S&P 500   4,207.15 (+0.04%)
DOW   32,967.71 (-0.38%)
QQQ   350.63 (+0.64%)
AAPL   177.48 (+1.17%)
MSFT   331.94 (-0.29%)
META   265.30 (+1.24%)
GOOGL   124.08 (-0.43%)
AMZN   121.41 (+1.08%)
TSLA   200.09 (+3.58%)
NVDA   404.68 (+3.91%)
NIO   7.41 (-3.77%)
BABA   78.70 (-2.80%)
AMD   125.92 (-0.87%)
T   15.65 (+0.97%)
F   12.70 (+5.05%)
MU   72.75 (-1.60%)
CGC   0.86 (-1.64%)
GE   102.03 (-0.69%)
DIS   87.44 (-0.96%)
AMC   4.52 (-2.59%)
PFE   37.10 (-1.33%)
PYPL   60.94 (+1.20%)
NFLX   391.31 (+3.28%)
S&P 500   4,207.15 (+0.04%)
DOW   32,967.71 (-0.38%)
QQQ   350.63 (+0.64%)
AAPL   177.48 (+1.17%)
MSFT   331.94 (-0.29%)
META   265.30 (+1.24%)
GOOGL   124.08 (-0.43%)
AMZN   121.41 (+1.08%)
TSLA   200.09 (+3.58%)
NVDA   404.68 (+3.91%)
NIO   7.41 (-3.77%)
BABA   78.70 (-2.80%)
AMD   125.92 (-0.87%)
T   15.65 (+0.97%)
F   12.70 (+5.05%)
MU   72.75 (-1.60%)
CGC   0.86 (-1.64%)
GE   102.03 (-0.69%)
DIS   87.44 (-0.96%)
AMC   4.52 (-2.59%)
PFE   37.10 (-1.33%)
PYPL   60.94 (+1.20%)
NFLX   391.31 (+3.28%)
S&P 500   4,207.15 (+0.04%)
DOW   32,967.71 (-0.38%)
QQQ   350.63 (+0.64%)
AAPL   177.48 (+1.17%)
MSFT   331.94 (-0.29%)
META   265.30 (+1.24%)
GOOGL   124.08 (-0.43%)
AMZN   121.41 (+1.08%)
TSLA   200.09 (+3.58%)
NVDA   404.68 (+3.91%)
NIO   7.41 (-3.77%)
BABA   78.70 (-2.80%)
AMD   125.92 (-0.87%)
T   15.65 (+0.97%)
F   12.70 (+5.05%)
MU   72.75 (-1.60%)
CGC   0.86 (-1.64%)
GE   102.03 (-0.69%)
DIS   87.44 (-0.96%)
AMC   4.52 (-2.59%)
PFE   37.10 (-1.33%)
PYPL   60.94 (+1.20%)
NFLX   391.31 (+3.28%)
S&P 500   4,207.15 (+0.04%)
DOW   32,967.71 (-0.38%)
QQQ   350.63 (+0.64%)
AAPL   177.48 (+1.17%)
MSFT   331.94 (-0.29%)
META   265.30 (+1.24%)
GOOGL   124.08 (-0.43%)
AMZN   121.41 (+1.08%)
TSLA   200.09 (+3.58%)
NVDA   404.68 (+3.91%)
NIO   7.41 (-3.77%)
BABA   78.70 (-2.80%)
AMD   125.92 (-0.87%)
T   15.65 (+0.97%)
F   12.70 (+5.05%)
MU   72.75 (-1.60%)
CGC   0.86 (-1.64%)
GE   102.03 (-0.69%)
DIS   87.44 (-0.96%)
AMC   4.52 (-2.59%)
PFE   37.10 (-1.33%)
PYPL   60.94 (+1.20%)
NFLX   391.31 (+3.28%)
NASDAQ:ILMN

Illumina (ILMN) Stock Forecast, Price & News

$194.75
-1.14 (-0.58%)
(As of 12:33 PM ET)
Compare
Today's Range
$194.10
$198.47
50-Day Range
$193.53
$232.67
52-Week Range
$173.45
$254.49
Volume
529,793 shs
Average Volume
1.29 million shs
Market Capitalization
$30.79 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$253.70

Illumina MarketRank™ Forecast

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
29.5% Upside
$253.70 Price Target
Short Interest
Healthy
2.72% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.42mentions of Illumina in the last 14 days
Based on 31 Articles This Week
Insider Trading
Selling Shares
$779,718 Sold Last Quarter
Proj. Earnings Growth
137.86%
From $1.40 to $3.33 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

98th out of 1,009 stocks

Analytical Instruments Industry

7th out of 29 stocks


ILMN stock logo

About Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

ILMN Stock News Headlines

Will Forced Divesture Of Grail Boost Illumina Shareholder Value?
Regulators may force Illumina to divest Grail, which it acquired in 2021. Carl Icahn is also calling for a divestiture. The move could benefit shareholders.
New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
Illumina (NASDAQ:ILMN) Stock Price Down 6.8%
12% Of This Illumina Insider's Holdings Were Sold
12% Of This Illumina Insider's Holdings Were Sold \
New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
Icahn Wins One Board Seat in Illumina Proxy Fight
Icahn Nominee Elected to Illumina’s Board
See More Headlines
Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

ILMN Company Calendar

Last Earnings
4/25/2023
Today
5/30/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:ILMN
CUSIP
45232710
Employees
10,260
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$253.70
High Stock Price Forecast
$350.00
Low Stock Price Forecast
$150.00
Forecasted Upside/Downside
+29.5%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
16 Analysts

Profitability

Net Income
$-4,404,000,000.00
Net Margins
-100.92%
Pretax Margin
-102.41%

Debt

Sales & Book Value

Annual Sales
$4.58 billion
Cash Flow
$4.64 per share
Book Value
$41.95 per share

Miscellaneous

Free Float
157,894,000
Market Cap
$30.97 billion
Optionable
Optionable
Beta
1.18

Social Links


Key Executives

  • Francis A. deSouzaFrancis A. deSouza
    Chief Executive Officer & Director
  • Kevin Pegels
    Chief-Global Operations
  • Joydeep Goswami
    CFO, Chief Strategy & Development Officer
  • Phillip G. FebboPhillip G. Febbo
    Chief Medical Officer
  • Alex Aravanis
    CTO, Head-Research & Product Development













ILMN Stock - Frequently Asked Questions

Should I buy or sell Illumina stock right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings
or view top-rated stocks.

What is Illumina's stock price forecast for 2023?

16 analysts have issued 1 year target prices for Illumina's shares. Their ILMN share price forecasts range from $150.00 to $350.00. On average, they expect the company's stock price to reach $253.70 in the next twelve months. This suggests a possible upside of 29.5% from the stock's current price.
View analysts price targets for ILMN
or view top-rated stocks among Wall Street analysts.

How have ILMN shares performed in 2023?

Illumina's stock was trading at $202.20 at the beginning of 2023. Since then, ILMN stock has decreased by 3.1% and is now trading at $195.89.
View the best growth stocks for 2023 here
.

When is Illumina's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ILMN earnings forecast
.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) issued its earnings results on Tuesday, April, 25th. The life sciences company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.06. The life sciences company earned $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a positive trailing twelve-month return on equity of 2.26% and a negative net margin of 100.92%. Illumina's quarterly revenue was down 11.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.07 EPS.
Read the conference call transcript
.

What guidance has Illumina issued on next quarter's earnings?

Illumina updated its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $1.25-$1.50 for the period, compared to the consensus EPS estimate of $1.41. The company issued revenue guidance of $4.91 billion-$5.04 billion, compared to the consensus revenue estimate of $4.93 billion.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (9.54%), Geode Capital Management LLC (1.85%), Select Equity Group L.P. (1.01%), Veritas Asset Management LLP (0.98%), Ownership Capital B.V. (0.69%) and Harding Loevner LP (0.69%). Insiders that own company stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Francis A Desouza, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Phillip G Febbo, Robert P Ragusa, Susan H Tousi and Susan H Tousi.
View institutional ownership trends
.

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $195.89.

How much money does Illumina make?

Illumina (NASDAQ:ILMN) has a market capitalization of $30.97 billion and generates $4.58 billion in revenue each year. The life sciences company earns $-4,404,000,000.00 in net income (profit) each year or ($28.53) on an earnings per share basis.

How many employees does Illumina have?

The company employs 10,260 workers across the globe.

Does Illumina have any subsidiaries?
The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Emedgene Inc., Emedgene Technologies Ltd, Enancio, Enancio SAS, Epicentre Biotechnologies, GRAIL LLC, GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More
How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The official website for the company is www.illumina.com. The life sciences company can be reached via phone at (858) 202-4500, via email at ir@illumina.com, or via fax at 858-202-4766.

This page (NASDAQ:ILMN) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -